Overview

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Byondis B.V.
Synthon Biopharmaceuticals BV
Treatments:
Trastuzumab